Profile data is unavailable for this security.
About the company
Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on seeds, improved plant traits, chemical and biological crop protection products, digital solutions and customer service for sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others.
- Revenue in USD (TTM)52.59bn
- Net income in USD-1.41bn
- Incorporated1952
- Employees96.57k
- LocationBayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
- Phone+49 214301
- Fax+49 2 143066328
- Websitehttps://www.bayer.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla Ltd | 3.13bn | 515.45m | 15.85bn | 27.76k | 30.76 | -- | 24.54 | 5.06 | 53.27 | 53.27 | 323.59 | -- | -- | -- | -- | 9,414,760.00 | -- | 10.09 | -- | 12.40 | 66.43 | 58.63 | 16.58 | 12.66 | -- | 59.65 | -- | 21.39 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Royalty Pharma plc | 2.24bn | 673.24m | 16.34bn | 89.00 | 18.31 | 1.91 | 19.46 | 7.30 | 1.50 | 1.50 | 3.74 | 14.42 | 0.1287 | -- | 76.10 | 25,141,870.00 | 5.92 | 9.57 | 7.77 | 12.42 | -- | -- | 46.02 | 67.80 | -- | -- | 0.4381 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 1.51bn | 422.34m | 17.20bn | 2.79k | 40.72 | 8.87 | -- | 11.37 | 4.94 | 4.94 | 17.68 | 22.66 | 0.6472 | 1.66 | 14.13 | 3,823,524.00 | 18.28 | 18.82 | 22.87 | 23.91 | 44.90 | 46.55 | 28.25 | 27.98 | 4.19 | -- | 0.0833 | 36.49 | 15.69 | 16.11 | 13.15 | 19.60 | 13.83 | 31.06 |
| Divi's Laboratories Ltd | 980.36m | 200.50m | 17.33bn | 17.50k | 86.45 | -- | 70.38 | 17.68 | 63.05 | 63.05 | 308.33 | -- | -- | -- | -- | 4,677,143.00 | -- | 16.55 | -- | 18.22 | 59.76 | 56.24 | 20.45 | 26.38 | -- | -- | -- | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Sandoz Group AG | -117.63bn | -117.63bn | 17.68bn | 23.85k | -- | 2.11 | -- | -- | -- | -- | -- | 16.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.7401 | -- | 0.3469 | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Teva Pharmaceutical Industries Ltd | 16.27bn | -475.54m | 20.10bn | 35.00k | -- | 3.16 | 65.33 | 1.24 | -1.57 | -1.57 | 54.58 | 21.20 | 0.3859 | 2.00 | 4.46 | 1,758,153.00 | -1.83 | -3.14 | -2.63 | -4.29 | 50.74 | 48.14 | -4.74 | -9.87 | 0.591 | 4.46 | 0.7396 | -- | 6.17 | -3.42 | 77.15 | -- | -4.17 | -- |
| Astellas Pharma Inc | 11.83bn | 149.53m | 21.84bn | 14.75k | 146.29 | 1.85 | 15.23 | 1.85 | 11.87 | 11.87 | 946.90 | 936.63 | 0.521 | 1.38 | 3.24 | 115,345,400.00 | 0.6587 | 4.59 | 1.03 | 6.61 | 81.51 | 80.53 | 1.26 | 7.98 | 0.7167 | 21.19 | 0.3719 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Biogen Inc | 9.67bn | 1.16bn | 29.04bn | 7.57k | 25.12 | 1.83 | 16.79 | 3.00 | 7.94 | 7.94 | 66.42 | 109.05 | 0.3723 | 1.23 | 4.60 | 1,277,675.00 | 4.46 | 12.53 | 5.07 | 14.83 | 75.54 | 83.04 | 11.97 | 26.93 | 1.48 | 2.87 | 0.2837 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Otsuka Holdings Co Ltd | 15.15bn | 881.19m | 30.71bn | 34.39k | 33.90 | 1.64 | 18.71 | 2.03 | 233.68 | 233.68 | 4,016.84 | 4,829.27 | 0.6256 | 2.34 | 4.50 | 63,393,040.00 | 3.76 | 4.80 | 4.70 | 5.88 | 70.66 | 68.21 | 6.01 | 8.36 | 1.66 | -- | 0.0851 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Bayer AG (ADR) | 52.59bn | -1.41bn | 31.43bn | 96.57k | -- | 0.7882 | 4.00 | 0.5976 | -0.3596 | -0.3596 | 13.38 | 10.14 | 0.3901 | 1.47 | 3.47 | 527,334.10 | -1.04 | -1.79 | -1.42 | -2.38 | 58.07 | 59.02 | -2.67 | -4.80 | 0.8573 | 2.94 | 0.5651 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -- |
| UCB SA | 6.09bn | 267.90m | 35.32bn | 9.08k | 132.25 | 3.45 | 33.88 | 5.80 | 1.23 | 1.23 | 27.92 | 47.19 | 0.3518 | 1.71 | 4.26 | 600,462.40 | 1.55 | 5.03 | 1.88 | 6.28 | 67.80 | 72.21 | 4.40 | 12.66 | 0.7806 | 3.15 | 0.2534 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.58bn | 769.50m | 38.64bn | 19.61k | 50.01 | 6.39 | -- | 10.79 | 0.854 | 0.854 | 3.98 | 6.68 | 0.5603 | 1.65 | 4.16 | 1,287,652.00 | 12.02 | 13.68 | 13.22 | 15.20 | 84.74 | 85.87 | 21.45 | 20.01 | 6.76 | -- | 0.0079 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
Data as of Sep 20 2024. Currency figures normalised to Bayer AG's reporting currency: US Dollar USD
0.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Eagle Capital Management LLCas of 06 Sep 2024 | 7.93m | 0.20% |
| Dodge & Coxas of 30 Jun 2024 | 4.63m | 0.12% |
| Kahn Brothers Advisors LLCas of 30 Jun 2024 | 4.37m | 0.11% |
| Altrius Capital Management, Inc.as of 30 Jun 2024 | 981.29k | 0.03% |
| Mcginn Penninger Investment Management, Inc.as of 30 Jun 2024 | 881.26k | 0.02% |
| Mediolanum International Funds Ltd.as of 28 Mar 2024 | 188.23k | 0.01% |
| Thompson, Siegel & Walmsley LLCas of 30 Jun 2024 | 180.00k | 0.01% |
| BlackRock Advisors LLCas of 20 Oct 2023 | 174.68k | 0.00% |
| Goldman Sachs Asset Management Internationalas of 30 Nov 2023 | 157.27k | 0.00% |
| Great Lakes Advisors LLCas of 30 Jun 2024 | 66.55k | 0.00% |
More ▼
Data from 30 Jun 2024 - 19 Sep 2024Source: FactSet Research Systems Inc.
